Biotech Exit: Million Arcellx Sparks Investor Reassessment
A notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
Conduct a value analysis of cash back cards with no fees to make smart financial choices. Understand the benefits and options available.
25,276 articlesA notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
Dream Finders’ bid for Beazer has evolved into a live governance case, testing board discretion against shareholder r...
A mid‑sized fund just boosted its stake in ServiceTitan after a sharp share drop. This article unpacks what the move ...
I’m a fan of Costco as a retailer, but my investing stance is stubbornly conservative. Here’s the core reason haven't...
Greg Abel delivers his first annual letter as Berkshire’s CEO, outlining continuity after a $4.5 billion write-down o...
As 2026 approaches, buyers and homeowners wonder if the market will slip further or stabilize. This guide breaks down...
Philip Morris International is steering a bold pivot toward smoke-free products, aiming to drive more than two-thirds...
Cursor CEO warns that relying on AI to bootstrap software—often labeled vibe coding—could create fragile foundations ...
A mom of four turns a global role into practical ways families can support kids in need. Learn how to align giving wi...
Rocket Lab stock remains volatile but disciplined investors see a path to a $150 milestone by 2027 as backlog grows a...
Dell Technologies surged 248% from year-end 2025 to midsummer 2026, sparking a parallel rally in the IGPT AI ETF. Thi...
Palo Alto Networks is trading lower as acquisition costs press on near-term guidance, even as AI security bets throug...